Skip to main content

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Publication ,  Journal Article
Love, C; Desai, NB; Abraham, T; Banks, KP; Bodei, L; Boike, T; Brown, RKJ; Bushnell, DL; DeBlanche, LE; Dominello, MM; Francis, T; Grady, EC ...
Published in: Am J Clin Oncol
June 1, 2022

OBJECTIVES: This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and progressed despite standard therapy. Lu-177 DOTATATE is a radiopharmaceutical with high avidity for somatostatin receptors that are overexpressed by these tumors. This document ensures safe handling of Lu-177 DOTATATE by the authorized users and safe management of affected patients. METHODS: The document was developed according to the systematic process developed by the American College of Radiology (ACR) and described on the ACR Web site (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards). The PP development was led by 2 ACR Committees on Practice Parameters (Nuclear Medicine and Molecular Imaging and Radiation Oncology) collaboratively with the American College of Nuclear Medicine, American Society of Radiation Oncology, and Society of Nuclear Medicine and Molecular Imaging. RESULTS: The Lu-177 DOTATATE PP reviewed pharmacology, indications, adverse effects, personnel qualifications, and required clinical evaluation before starting the treatment, as well as the recommended posttherapy monitoring, quality assurance, documentation, and appropriate radiation safety instructions provided in written form and explained to the patients. CONCLUSIONS: Lu-177 DOTATATE is available for therapy of inoperable and/or advanced GEP-NETs when conventional therapy had failed. It can reduce tumor size, improve symptoms, and increase the progression free survival. The PP document provides clinical guidance for authorized users to assure an appropriate, consistent, and safe practice of Lu-177 DOTATATE.

Duke Scholars

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

June 1, 2022

Volume

45

Issue

6

Start / End Page

233 / 242

Location

United States

Related Subject Headings

  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Radioisotopes
  • Positron-Emission Tomography
  • Oncology & Carcinogenesis
  • Neuroendocrine Tumors
  • Lutetium
  • Humans
  • Adult
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Love, C., Desai, N. B., Abraham, T., Banks, K. P., Bodei, L., Boike, T., … Schechter, N. R. (2022). ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol, 45(6), 233–242. https://doi.org/10.1097/COC.0000000000000903
Love, Charito, Neil B. Desai, Tony Abraham, Kevin P. Banks, Lisa Bodei, Thomas Boike, Richard K. J. Brown, et al. “ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.Am J Clin Oncol 45, no. 6 (June 1, 2022): 233–42. https://doi.org/10.1097/COC.0000000000000903.
Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, et al. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol. 2022 Jun 1;45(6):233–42.
Love, Charito, et al. “ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.Am J Clin Oncol, vol. 45, no. 6, June 2022, pp. 233–42. Pubmed, doi:10.1097/COC.0000000000000903.
Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Am J Clin Oncol. 2022 Jun 1;45(6):233–242.

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

June 1, 2022

Volume

45

Issue

6

Start / End Page

233 / 242

Location

United States

Related Subject Headings

  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Radioisotopes
  • Positron-Emission Tomography
  • Oncology & Carcinogenesis
  • Neuroendocrine Tumors
  • Lutetium
  • Humans
  • Adult
  • 3211 Oncology and carcinogenesis